Trial Profile
A Phase IIa Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs K 134 (Primary) ; Cilostazol
- Indications Embolism and thrombosis; Intermittent claudication
- Focus Therapeutic Use
- 21 Mar 2012 Actual patient number is 387 according to ClinicalTrials.gov.
- 10 Nov 2011 Results were reported at the American Heart Association Scientific Sessions, according to a Kowa media release.
- 01 Jul 2010 Status changed from active, no longer recruiting to completed.